Cardiovascular magnetic resonance in muscular dystrophies: looking ahead

Submitted: November 19, 2023
Accepted: January 25, 2024
Published: February 2, 2024
Abstract Views: 190
PDF_EARLY VIEW: 112
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Cardiac magnetic resonance (CMR) is an established tool for risk stratification in several cardiomyopathies, and its role in muscular dystrophies (MuD) looks promising. We sought to assess how CMR performs in predicting cardiac events in a real cohort of MuD patients. A prospective single-center study with the enrollment of consecutive adult MuD patients referred to cardiac screening from 2012 to 2018 with the collection of clinical and CMR data. During follow-up (FUP), major adverse cardiac events were considered a composite of device implantation, ventricular tachycardia (VT), hospitalization due to heart failure, and death. Sixty-five patients were included (mean age of 32±16, 51% female); the majority had myotonic dystrophy (34; 52.3%); most were asymptomatic (60; 92.3%) and at sinus rhythm (64; 98.5%). CMR was abnormal in 23 (43.3%) patients: left ventricle ejection fraction (LVEF) <55% was found in 7 patients, and late gadolinium enhancement (LGE) was present in 23 patients, mainly intra-myocardial or subepicardial (10 and 8 patients, respectively). During a median FUP of 77 months (interquartile range: 33), there were 7 deaths, 8 implanted devices, and one sustained VT. LVEF<55% and the presence of LGE were associated with the occurrence of all events (log rank test, p=0.002 and p=0.045, respectively). LVEF<55% was associated with a 6-fold higher risk of events (crude hazard ratio of 6.15; 95% confidence interval of 1.65-22.93), that remained significant after adjusting for LGE presence (adjusted hazard ratio of 4.81, 95% confidence interval of 1.07-15.9). In our cohort, CMR LVEF<55% and the presence of LGE were significantly associated with adverse events during follow-up, reinforcing the role of this technique on risk stratification of MuD populations.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Morrison BM. Neuromuscular diseases. Semin Neurol 2016;36:409-18. DOI: https://doi.org/10.1055/s-0036-1586263
Verhaert D, Richads K, Rafael-Fortney, Raman SV. Cardiac involvement in patients with muscular dystrophies. Circ Cardiovasc Imaging 2011;4:67-76. DOI: https://doi.org/10.1161/CIRCIMAGING.110.960740
Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022;43:3997-4126. DOI: https://doi.org/10.1093/eurheartj/ehac699
Ismail H, Raynor E, Zimetbaum P. Neuromuscular disorders and the role of the clinical electrophysiologist. JACC Clin Electrophysiol 2017;3:1069-79. DOI: https://doi.org/10.1016/j.jacep.2017.04.023
Lamacie MM, Warman-Chardon J, Crean AM, et al. The added value of cardiac magnetic resonance in muscular dystrophies. J Neuromuscul Dis 2019;6:389-99. DOI: https://doi.org/10.3233/JND-190415
Grigoratos C, Aimo A, Barison A, et al. Cardiac magnetic resonance in patients with muscular dystrophies. Eur J Prev Cardiol 2021;28:1526-35. DOI: https://doi.org/10.1177/2047487320923052
Silva MC, Meira ZM, Gurgel Giannetti J, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. J Am Coll Cardiol 2007;49:1874-9. DOI: https://doi.org/10.1016/j.jacc.2006.10.078
Hermans MC, Faber CG, Bekkers SC, et al. Structural and functional cardiac changes in myotonic dystrophy type 1: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2012;14:48. DOI: https://doi.org/10.1186/1532-429X-14-48
Feingold B, Mahle WT, Auerbach S, et al. Management of cardiac involvement associated with neuromuscular diseases: a scientific statement from the american heart association. Circulation 2017;136:e200-31. DOI: https://doi.org/10.1161/CIR.0000000000000526
Florian A, Ludwig A, Engelen M, et al. Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patients. J Cardiovasc Magn Reson 2014;16:81. DOI: https://doi.org/10.1186/s12968-014-0081-1
Yilmaz A, Gdynia HJ, Baccouche H, et al. Cardiac involvement in patients with Becker muscular dystrophy: new diagnostic and pathophysiological insights by a CMR approach. J Cardiovasc Magn Reson 2008;10:50. DOI: https://doi.org/10.1186/1532-429X-10-50
Matsumura T, Tamura T, Kuru S, et al. Carvedilol can prevent cardiac events in duchenne muscular dystrophy. Intern Med 2010;49:1357-63. DOI: https://doi.org/10.2169/internalmedicine.49.3259
D’Amario D, Amodeo A, Adorisio R, et al. A current approach to heart failure in Duchenne muscular dystrophy. Heart 2017;103:1770-9. DOI: https://doi.org/10.1136/heartjnl-2017-311269

Ethics Approval

The research protocol was approved by Hospital do São João Ethics Committee on the 21st of September 2012, and patients’ consent was acquired. The study was performed according to the recommendations of Helsinki Declaration.

How to Cite

Amador, Ana Filipa, Teresa Pinho, Catarina Martins da Costa, António José Madureira, and Elisabete Martins. 2024. “Cardiovascular Magnetic Resonance in Muscular Dystrophies: Looking Ahead”. Monaldi Archives for Chest Disease, February. https://doi.org/10.4081/monaldi.2024.2851.